San Francisco-based SoundHealth raised an oversubscribed $12.25M Series A led by Shangbay Capital to expand its portfolio of FDA-cleared, AI-powered acoustic wearables. Flagship device Sonu, a personalized nasal band using smartphone craniofacial scanning and acoustic resonance, has delivered 500,000+ treatment sessions and is the leading non-drug alternative to corticosteroid sprays for allergic and non-allergic rhinitis. SoundHealth is recommended by 1,000+ medical and dental professionals nationwide.
The company's technology combines computer vision (smartphone facial scan) with AI to map a user's unique sinus anatomy, then delivers personalized acoustic vibrations tuned to that individual's resonant frequencies. New product Spatial Sleep extends the same craniofacial resonance mapping to sleep health—acoustic signals tailored to facial geometry to accelerate sleep onset and extend duration. Both products avoid the rebound congestion, systemic side effects, and habituation that plague prolonged use of steroid sprays, decongestants, and sedative sleep aids.
For architects of medical AI, SoundHealth is a clear example of defensible wearable moat: the proprietary dataset of 500K+ anatomical scans and treatment outcomes, combined with personalized algorithms, creates switching costs. Shangbay's $12.25M bet signals confidence in scaling a hardware-software medical device beyond the initial rhinitis market into sleep—a multi-billion category with minimal non-drug competition.